Hormonal management of premenstrual syndrome

Usman, Sa'adatu Bose; Indusekhar, Radha; O’Brien, Shaughn

doi:10.1016/j.bpobgyn.2007.07.001

Cited by 25 publications

(21 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many women experience symptoms during their reproductive years, resulting from fluctuations in hormone levels during the cycle [17][18][19][20] . It is estimated that PMS affects up to 80-90% of women, while dysmenorrhoea can affect 50-90% of young women and causes regular absenteeism from school or work 18 .…”

Section: Discussionmentioning

confidence: 99%

Clinical experience with the combined contraceptive vaginal ring in Switzerland, including a subgroup analysis of previous hormonal contraceptive use

Merki‐Feld¹,

Hund

2010

The European Journal of Contraception & Reproductive Health

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical experience with the combined contraceptive vaginal ring in Switzerland, including a subgroup analysis of previous hormonal contraceptive use

Merki‐Feld¹,

Hund

2010

The European Journal of Contraception & Reproductive Health

View full text Add to dashboard Cite

show abstract

“…At least one premenstrual symptom occurs in 95% of women of reproductive age [3] . The main treatment strategies involve ovulation suppression or targeting the central nervous system components that are thought to be involved in the etiology of PMS [4] . As demonstrated by several clinical studies, PMS patients hypersecrete prolactin in response to the pressures of daily life, which leads to an unphysiological stimulation of the mammary gland, thereby causing mastodynia [5] .…”

Section: Introductionmentioning

confidence: 99%

Casticin, a flavonoid isolated from Vitex rotundifolia, inhibits prolactin release in vivo and in vitro

Zhang

Zheng

et al. 2010

Acta Pharmacol Sin

View full text Add to dashboard Cite

Aim: To investigate the anti-hyperprolactinemia activity of casticin, a flavonoid isolated from Vitex rotundifolia, and elucidate its molecular mechanism. Methods: Hyperprolactinemia (MIHP) was induced by administration of metoclopramide dihydrochloride (50 mg/kg, tid, ip, for 10 d) in SD rats and the primary pituitary cells were prepared from the pituitary glands of the SD rats. Prolactin concentrations were measured using a radioimmunoassay. Cell viability was measured using an MTT assay. The mRNA expression of estrogen receptor alpha and beta in rat pituitary cells was measured using semi-quantitative RT-PCR analysis. Results: The level of serum prolactin in the MIHP model group was 2.1 fold higher than that in the untreated control group (P<0.01). Casticin (10, 20, and 40 mg/kg, ip, for 7 d) reduced serum prolactin levels by 33.9%, 54.3%, and 64.7%, respectively (P<0.01). The positive control drug bromocriptine 1 mg/kg decreased the serum prolactin concentration in MIHP rats by 44.9%. 17β-Estradiol (E2) significantly increased the proliferation of pituitary cells and casticin (1 and 10 μmol/L) markedly inhibited E2-induced pituitary cell proliferation by 27.7% and 42.1%, respectively. Stimulation of pituitary cells with E2 increased prolactin secretion into the cell culture supernatants, and casticin (0.1, 1, and 10 μmol/L) significantly inhibited the prolactin release stimulated by E2 in a concentration-dependent manner. Casticin (1 and 10 μmol/L) significantly inhibited ERα mRNA expression in pituitary cells stimulated with E2 (P<0.01) but increased ERβ mRNA expression at a concentration of 10 μmol/L (P<0.01). However, casticin had no effects on proliferation and prolectin release of the unstimulated primary pituitary cells in vitro. Conclusion: Casticin inhibited the release of prolactin from pituitary cells of SD rats stimulated with E2 in vivo and in vitro. These effects might be related with inhibiting the ERα mRNA expression and increasing the ERβ mRNA expression.

show abstract

“…Despite the uniformly high effectiveness of COCs in inhibiting ovulation, COCs as a class are not effective in alleviating PMS symptoms [32,33], and some preparations may cause PMS-like symptoms [33]. This is likely the result of enhanced progesterone-progestin sensitivity, which can be exacerbated by neurotransmitter dysfunction [34]. However, a 20-μg ethinyl estradiol pill containing 3 mg of drospirenone in a 24/4 regimen (Yaz; Bayer Healthcare, Wayne, NJ) recently has been shown to relieve symptoms of PMDD, and was approved by the FDA for the treatment of the symptoms of PMDD in women who wish to use the pill for contraception.…”

Section: Medical Interventionsmentioning

confidence: 98%

Gynecological Management of Premenstrual Symptoms

Shulman

2010

Curr Pain Headache Rep

View full text Add to dashboard Cite

The vast majority of menstruating women experience uncomfortable symptoms during the premenstrual phase of their menstrual cycles. Although many women do not require specific treatment of their symptoms, approximately 20% to 50% report moderate to severe premenstrual symptoms and about 5% meet the diagnostic criteria for premenstrual dysphoric disorder, the most severe manifestation of premenstrual symptoms. While the etiology of premenstrual symptoms remains unclear, several theories have implicated sex steroids and neurotransmitters in the development and manifestation of symptoms. Further complicating the delineation of etiology is that premenstrual symptoms can be somatic, psychological, or behavioral, as well as a combination of all three. Developing successful interventions for premenstrual symptoms has thus been challenging, with interventions focused on a particular aspect of premenstrual symptomatology. Treatments for premenstrual symptoms include lifestyle changes, cognitive behavioral therapies, and pharmacologic agents including ovulation suppression regimens, antidepressant medications, and anxiolytics.

show abstract

Hormonal management of premenstrual syndrome

Cited by 25 publications

References 47 publications

Clinical experience with the combined contraceptive vaginal ring in Switzerland, including a subgroup analysis of previous hormonal contraceptive use

Clinical experience with the combined contraceptive vaginal ring in Switzerland, including a subgroup analysis of previous hormonal contraceptive use

Casticin, a flavonoid isolated from Vitex rotundifolia, inhibits prolactin release in vivo and in vitro

Gynecological Management of Premenstrual Symptoms

Contact Info

Product

Resources

About